Velu Nair1, Ajay Sharma2, Jyoti Kotwal3, M Bhikshapathy4, D K Mishra5, Satyaranjan Das6, Sanjeevan Sharma6, Rajan Kapoor6, Jasjit Singh6, Vivek Nair7, Y Uday8, Atul Kotwal9. 1. Dean & Deputy Commandant, Armed Forces Medical College, Pune 411040, India. 2. Consultant (Medicine & Clinical Hematology), Army Hospital (R&R), Delhi Cantt 110010, India. 3. Senior Advisor, (Pathology & Hematopathologist), Army Hospital (R&R), Delhi Cantt 110010, India. 4. Army Hospital (R&R), Delhi Cantt 110010, India. 5. Ex-Senior Advisor (Pathology & Hematopathologist), Army Hospital (R&R), Delhi Cantt 110010, India. 6. Clinical Hematologist, Army Hospital (R&R), Delhi Cantt 110010, India. 7. Senior Resident (Dermatology), Maulana Azad Medical College, New Delhi 110002, India. 8. Senior Resident (Clinical Hematology), PGIMER, Chandigarh, India. 9. Director, AFMS (Med Research), O/o DGAFMS, Ministry of Defence, New Delhi, India ; Professor and Head, Dept of Community Medicine, Army College of Medical Sciences, New Delhi 11001, India.
Abstract
BACKGROUND: The BCR-ABL tyrosine kinase is a well validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (IM), a tyrosine kinase inhibitor is highly effective in the treatment of chronic phase CML. BCR - ABL transcripts have been well established as a molecular marker to document response to therapy in CML. Periodic monitoring of this marker helps in evolving therapeutic strategies with IM and also in diagnosing early relapse. This study was undertaken to monitor therapeutic response to IM in CML in chronic phase (CML-CP) by assessing BCR-ABL by real time quantitative PCR (RQ-PCR) techniques and to determine the effectiveness of the Indian generic IM. METHODS: One hundred consecutive patients of CML in chronic phase (CML-CP) were treated with an Indian generic of IM. Eighty-five patients were evaluable at 12 months of therapy. At entry, diagnosis of CML-CP was confirmed by FISH and RQ-PCR. Response to therapy was monitored by assessing BCR-ABL levels by RQ-PCR at 6 and 12 months of therapy. Regular follow up of patients was done to evaluate the safety profile of IM used in these patients. RESULTS: Complete hematological response (CHR) rates at 3, 6, 9 and 12 months were 92%, 94%, 100% and 100% respectively. The total molecular response at 12 months was 43.52% of which complete molecular response (CMR) was noted in 17.64% and major molecular response (MMR) was observed in 25.88%. A cumulative survival probability of 0.8 was observed. CONCLUSION: The Indian generic molecule of IM is effective in the treatment of CML-CP. The cost of Indian generic molecule is less than Rs. 10,000 per month there by making this affordable for large number of CML-CP patients in India.
BACKGROUND: The BCR-ABL tyrosine kinase is a well validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (IM), a tyrosine kinase inhibitor is highly effective in the treatment of chronic phase CML. BCR - ABL transcripts have been well established as a molecular marker to document response to therapy in CML. Periodic monitoring of this marker helps in evolving therapeutic strategies with IM and also in diagnosing early relapse. This study was undertaken to monitor therapeutic response to IM in CML in chronic phase (CML-CP) by assessing BCR-ABL by real time quantitative PCR (RQ-PCR) techniques and to determine the effectiveness of the Indian generic IM. METHODS: One hundred consecutive patients of CML in chronic phase (CML-CP) were treated with an Indian generic of IM. Eighty-five patients were evaluable at 12 months of therapy. At entry, diagnosis of CML-CP was confirmed by FISH and RQ-PCR. Response to therapy was monitored by assessing BCR-ABL levels by RQ-PCR at 6 and 12 months of therapy. Regular follow up of patients was done to evaluate the safety profile of IM used in these patients. RESULTS: Complete hematological response (CHR) rates at 3, 6, 9 and 12 months were 92%, 94%, 100% and 100% respectively. The total molecular response at 12 months was 43.52% of which complete molecular response (CMR) was noted in 17.64% and major molecular response (MMR) was observed in 25.88%. A cumulative survival probability of 0.8 was observed. CONCLUSION: The Indian generic molecule of IM is effective in the treatment of CML-CP. The cost of Indian generic molecule is less than Rs. 10,000 per month there by making this affordable for large number of CML-CPpatients in India.
Entities:
Keywords:
CML-CP; Imatinib mesylate; Major molecular response; RQ-PCR
Authors: Letizia Foroni; Gill Wilson; Gareth Gerrard; Joanne Mason; David Grimwade; Helen E White; David Gonzalez de Castro; Stephen Austin; Abida Awan; Emma Burt; Tim Clench; Joanna Farruggia; Jeremy Hancock; Alexandra E Irvine; Aytug Kizilors; Stephen Langabeer; Benedict J Milner; Guillermina Nickless; Anna Schuh; Anne Sproul; Lihui Wang; Caroline Wickham; Nicholas C P Cross Journal: Br J Haematol Date: 2011-03-08 Impact factor: 6.998
Authors: M Emig; S Saussele; H Wittor; A Weisser; A Reiter; A Willer; U Berger; R Hehlmann; N C Cross; A Hochhaus Journal: Leukemia Date: 1999-11 Impact factor: 11.528
Authors: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; Francois Guilhot; Charles A Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman Journal: Blood Date: 2006-03-07 Impact factor: 22.113
Authors: Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245